live sessions
PDT:
Pacific Daylight Time
PDT:
Pacific Daylight Time
Monday (March 10) Sessions
Live Now:
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Monday
Diane V. Havlir
University of California San Francisco, San Francisco, CA, USA
8:35 AM8:35 AM
16 - HIV Cure: A Translational Research Perspective
Ole Søgaard
Aarhus University, Aarhus, Denmark
9:05 AM9:05 AM
17 - The Global HIV/AIDS Pandemic: Where Are We Now?
Chris Beyrer
Duke Global Health Institute, Durham, NC, USA
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
HIV Reservoirs and Cure Strategies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
100 - 5’Leader Defects in HIV Plasma Clones Drive 80% of Persistent Viremia on Long-Term ART
Francesco R. Simonetti
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:13 AM10:13 AM
101 - BACH2-Driven Tissue Resident Memory Programs Promote HIV-1 Persistence
Yulong Wei
Yale University, New Haven, CT, USA
10:21 AM10:21 AM
102 - Longitudinal Co-Evolution of HIV-1 Reservoir Cells and Immune Effector Cells During Long-Term Art
Weiwei Sun
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
10:29 AM10:29 AM
103 - AZD5582 and Venetoclax Reduce SIV Reservoirs in ART-Suppressed Macaques
Benedicth Ukhueduan
Emory University, Atlanta, GA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
104 - HIV GAG x CD3 Soluble TCR Bispecific Reduces the Active HIV Reservoir in a Phase I/II Trial
Beatriz Mothe
Fundació Lluita contra la SIDA, Badalona, Spain
11:08 AM11:08 AM
105 - Evaluation of 2 bNAbs Plus Vesatolimod in Early-Treated South African Women With HIV-1 During ATI
Thumbi Ndung'u
Africa Health Research Institute, Mtubatuba, South Africa
11:16 AM11:16 AM
106 - A Single Infusion of CCR5-/- CD4 Tscm Cells Promotes Control of SIV Upon ATI
Ashish A. Sharma
Emory University, Atlanta, GA, USA
11:24 AM11:24 AM
107 - RIO: A Randomised Placebo-Controlled Study of 2 LS-bNAbs in People Treated in Early HIV
Sarah Fidler
Imperial College London, London, UK
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
The Coinfections: Hepatitis and TB
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
108 - Trends in Hepatitis C Virus (HCV) Infection Incidence Among PWH Engaged in Care in the US: 1995-2023
Yotam Arens
Weill Cornell Medicine, New York, NY, USA
10:13 AM10:13 AM
109 - HIV Decreases Both Hepatitis B Antibody Titer and Neutralization After Spontaneous HBV Control
Chloe Thio
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
110 - HBV Care Continuum and Associated Factors in Rwanda: A Population-Based Study From 2016-2023
Jean Damascene Makuza
University of British Columbia, Vancouver, Canada
10:29 AM10:29 AM
111 - Intrahepatic Transcriptomics in HBV-HIV Co-Infection Uncover Host Responses to HBV Transcription
Che-Min Lo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
112 - Highly Durable Seroprotection With HepB-CpG Vaccine in People With HIV (PWH): ACTG A5379 (BEeHIVe)
Kristen Marks
Weill Cornell Medicine, New York, NY, USA
11:08 AM11:08 AM
113 - Epigenetic Age Predictors of Semaglutide-Related Liver Fat Changes in People With HIV
Alina Pang
Weill Cornell Medicine, New York, NY, USA
11:16 AM11:16 AM
114 - Supplemental High-Dose Rifampicin and Levofloxacin for Inpatients With Disseminated HIV-TB
Graeme Meintjes
University of Cape Town, Cape Town, South Africa
11:24 AM11:24 AM
115 - Casual Contact in Community Settings Explains Majority of TB Transmission in South Africa
Neel R. Gandhi
Emory University, Atlanta, GA, USA
11:32 AM11:32 AM
116 - DOLPHIN-Moms: Pharmacokinetics of Dolutegravir and HIV Viral Suppression With 1HP or 3HP in Pregnancy
Jyoti Mathad
Weill Cornell Medicine, New York, NY, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Maternal-Child Health and Treatment of Malignancies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
117 - Maternal Tenofovir Prophylaxis With Active Immunization to Prevent Infant Hepatitis B
Gonzague Jourdain
Chiang Mai University, Chiang Mai, Thailand
10:13 AM10:13 AM
118 - Efficacy of Home Visits for Pregnant Couples to Promote Couple HIV Testing and Family Health
Lynae Darbes
University of Michigan, Ann Arbor, MI, USA
10:21 AM10:21 AM
119 - Dolutegravir Does Not Reduce Levonorgestrel or Medroxyprogesterone Acetate Concentrations in WLWH
Rebecca Ryan
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
10:29 AM10:29 AM
120 - Lenacapavir Pharmacokinetics, Safety, and Efficacy in Adolescents and Adults in PURPOSE 1
Katherine Gill
Desmond Tutu HIV Foundation, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
121 - Assessing IIT and Mortality Among CLHIV <15 yo in PEPFAR-Supported Countries, FY21 - FY24
Michelle Yang
US Department of State, Washington, DC, USA
11:08 AM11:08 AM
122 - Multidose PK/Safety of Dolutegravir Dispersible Tablets & Oral Films in Neonates: PETITE-DTG Study
Adrie Bekker
Stellenbosch University, Cape Town, South Africa
11:16 AM11:16 AM
123 - Genotypic Resistance in the African Paediatric CHAPAS-4 Trial of Second-Line Antiretroviral Therapy
Alasdair Bamford
Great Ormond Street NHS Foundation Trust, London, UK
11:24 AM11:24 AM
124 - Abemaciclib, a CDK4/6 Inhibitor, in HIV-Associated and HIV-Negative Kaposi Sarcoma
Jose R. Mercado-Matos
National Cancer Institute, Bethesda, MD, USA
11:32 AM11:32 AM
125 - Differences in Treatment and Overall Survival in People With and Without HIV and Oropharynx Cancer
Elizabeth Chiao
University of Texas MD Anderson Cancer Center, Houston, TX, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Evolution of HIV and Mpox Epidemics
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
126 - Comparing Empirical HIV Incidence With UNAIDS Estimated Incidence Declines in Sub-Saharan Africa
Oliver Stevens
Imperial College London, London, UK
10:21 AM10:21 AM
128 - All-Cause and Cause-Specific Mortality Trends Among Persons With and Without HIV in Rural Tanzania
Julie Ambia
University of Bristol, Bristol, UK
10:29 AM10:29 AM
129 - Associations of Dolutegravir and the COVID-19 Pandemic on Viral Suppression in South African Adults
Haroon Moolla
University of Cape Town, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
130 - A Multistage Sampling Approach to Refine HIV Mortality Estimates in KwaZulu-Natal, South Africa
Alastair VanHeerden
Human Sciences Research Council, Pretoria, South Africa
11:08 AM11:08 AM
131 - Genotypic Characterization of Mpox and a Tale of 2 Co-Circulating Viruses in Uganda
Nicholas Bbosa
London School of Hygiene & Tropical Medicine, London, UK
11:16 AM11:16 AM
132 - Characterization of Mpox Cases in Uganda: Diversity of the Confirmed Cases
Ritah Namusoosa
Ministry of Health Uganda, Kampala, Uganda
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Down But Not Out: Elite Control of HIV
1:30 PM1:30 PM
(Session Overview)
Javier Martinez-Pìcado
IrsiCaixa, Badalona, Spain
1:35 PM1:35 PM
495 - Effect of ART Start Time, ART Duration, and Elite Control on HIV Transcription
Adam Wedrychowski
San Francisco VA Medical Center, San Francisco, CA, USA
1:40 PM1:40 PM
496 - Viral Reservoir Characteristics in Lymphoid Tissues of HIV-1 Elite Controllers
Samantha K. Marzi
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
1:45 PM1:45 PM
497 - CD8+ T Cells Shape the HIV Integration Site Landscape According to the Degree of T-Cell Pressure
Noemi L. Linden
Weill Cornell Medicine, New York, NY, USA
1:50 PM1:50 PM
498 - Anti-IL-10/Anti-PD-1 Dual Blockade Leads to IFN-Related HIV Elite Control Signatures
Susan P. Ribeiro
Emory University, Atlanta, GA, USA
1:55 PM1:55 PM
494 - Loss of Virological Control 32 Years After HIV-1 Diagnosis in an Exceptional Elite Controller
Anna Pons-Grífols
IrsiCaixa, Badalona, Spain
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Heart Failure: Hiding in Plain Sight
1:30 PM1:30 PM
(Session Overview)
Anoop Shah
London School of Hygiene & Tropical Medicine, London, UK
1:35 PM1:35 PM
813 - Mitochondrial Haplogroups and Left Ventricular Dysfunction in People Living With and Without HIV
Craig Cronin
The Johns Hopkins Hospital, Baltimore, MD, USA
1:40 PM1:40 PM
811 - Sex Differences in Myocardial Steatosis in South African Youth With Perinatally-Acquired HIV
Morne Kahts
University of Cape Town, Cape Town, South Africa
1:45 PM1:45 PM
814 - Physician-Confirmed Incident Heart Failure Phenotypes and Etiologies Within CNICS
Matthew J. Feinstein
Northwestern University, Chicago, IL, USA
1:50 PM1:50 PM
815 - Readmission Risk for Adults With HIV Hospitalized for Heart Failure or Acute Myocardial Infarction
Ping Yang
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:55 PM1:55 PM
812 - Heart Failure Among People With HIV: Prescription of Guideline-Directed Medical Therapy
Melissa K. Cutshaw
Duke University School of Medicine, Durham, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
KS and KSHV: New Developments in Diagnosis, Therapy, and Pathogenesis
1:30 PM1:30 PM
(Session Overview)
Robert Yarchoan
National Institutes of Health, Bethesda, MD, USA
1:35 PM1:35 PM
789 - Validation of Quantification of Lesional KSHV DNA Content for Diagnosis of Kaposi Sarcoma in Africa
Aggrey Semeere
Infectious Diseases Institute, Kampala, Uganda
1:40 PM1:40 PM
792 - Impact of Low-Dose Intra-Lesional Nivolumab for Kaposi Sarcoma on T-Cell Proliferation and Function
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
1:45 PM1:45 PM
791 - Immunologic Responses to Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma Treatment
Matthew Witterholt
National Cancer Institute, Bethesda, MD, USA
1:50 PM1:50 PM
794 - Causes of Death Among Adults With HIV-Associated Kaposi Sarcoma in East Africa in the Treat All Era
Hilda Muwando
Infectious Diseases Institute, Kampala, Uganda
1:55 PM1:55 PM
796 - Genome Evolution of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in PLWH
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Meeting the Treatment and Prevention Needs of Transgender Women
1:30 PM1:30 PM
(Session Overview)
Tonia Poteat
Duke University, Durham, NC, USA
1:35 PM1:35 PM
1108 - Recent HIV Acquisition Among Transgender Women From Midwest Brazil
Sylvia L. M. Teixeira
Oswaldo Cruz Institute – Fiocruz, Rio de Janeiro, Brazil
1:45 PM1:45 PM
1109 - High HIV Burden Among Transgender Women in the State Capital and Rural Towns in Central Brazil
Bruno Vinícius D. Diniz e Silva
Federal University of Goias, Goiânia, Brazil
1:50 PM1:50 PM
1110 - Time to Antiretroviral Initiation Among Transgender Women Living With HIV in France (1997-2022)
Juliette Hemery
French National Institute of Health and Medical Research (Inserm), Paris, France
1:55 PM1:55 PM
Discussion with Audience Q&A
1:30 PM1:30 PM
(Session Overview)
Mateo Prochazka
World Health Organization, Geneva, Switzerland
1:40 PM1:40 PM
1178 - National HIV Self-Test Distribution Program: HIV Testing, Diagnosis and Treatment, 3/2023 - 5/2024
Patrick S. Sullivan
Emory University, Atlanta, GA, USA
1:45 PM1:45 PM
1179 - Estimating Need for Annual HIV Testing Met by a Nationwide Mailed HIV Self-Testing Program
Jen Hecht
1:50 PM1:50 PM
1181 - Moderators of a Home-Based Couple Intervention on Couple HIV Testing and Counselling Uptake in Kenya
Zachary A. Kwena
Kenya Medical Research Institute-UCSF Infectious Disease Research Training Program, Kisumu, Kenya
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Deciphering the Mystery of Viral Rebound
4:00 PM4:00 PM
18 - Utilizing a Barcoded Virus Model to Identify the Source of Viral Rebound
Brandon Keele
Frederick National Laboratory for Cancer Research, Frederick, MD, USA
4:20 PM4:20 PM
19 - Cellular and Tissue Sources of Viral Persistence and Rebound
Linos Vandekerckhove
HIV Cure Research Center, Ghent University, Ghent, Belgium
4:40 PM4:40 PM
20 - Immune Responses During Viral Rebound
Rachel Rutishauser
University of California San Francisco, San Francisco, CA, USA
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Filling the Gaps: Challenges and Opportunities in the Care of Children and Youth With Perinatal HIV
4:00 PM4:00 PM
21 - Advanced HIV Disease in Children
Pablo Rojo
Hospital Universitario 12 de Octubre, Madrid, Spain
4:20 PM4:20 PM
22 - HIV Care Continuum in Children
Irene Njuguna
University of Washington, Seattle, WA, USA
4:40 PM4:40 PM
23 - Sexual, Reproductive, and Pregnancy Health Among People With Perinatal HIV
Caroline Foster
Imperial College Healthcare NHS Trust, London, UK
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Closing the Gaps in the HIV Response
4:00 PM4:00 PM
24 - Immediate Challenges and Long-Term Goals of the HIV Response
Jeffrey Imai-Eaton
Harvard TH Chan School of Public Health
4:20 PM4:20 PM
25 - Integration and Sustainability of the Global HIV Response
Tsitsi Apollo
Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe
4:40 PM4:40 PM
26 - Innovations in HIV Service Delivery: Building a Path Forward with Those Left Behind
Izukanji Sikazwe
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestMiddleName 2 TestLastName 2
Institution 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 3 TestMiddleName 3 TestLastName 3
Institution 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 4 TestMiddleName 4 TestLastName 4
Institution 4
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestMiddleName 2 TestLastName 2
Institution 2
Upcoming:
MAR10
8:30 AMto9:30 AMPDT
12:00 PMto5:00 PMPDT
Monday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Monday
Diane V. Havlir
University of California San Francisco, San Francisco, CA, USA
8:35 AM8:35 AM
16 - HIV Cure: A Translational Research Perspective
Ole Søgaard
Aarhus University, Aarhus, Denmark
9:05 AM9:05 AM
17 - The Global HIV/AIDS Pandemic: Where Are We Now?
Chris Beyrer
Duke Global Health Institute, Durham, NC, USA
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
HIV Reservoirs and Cure Strategies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
100 - 5’Leader Defects in HIV Plasma Clones Drive 80% of Persistent Viremia on Long-Term ART
Francesco R. Simonetti
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:13 AM10:13 AM
101 - BACH2-Driven Tissue Resident Memory Programs Promote HIV-1 Persistence
Yulong Wei
Yale University, New Haven, CT, USA
10:21 AM10:21 AM
102 - Longitudinal Co-Evolution of HIV-1 Reservoir Cells and Immune Effector Cells During Long-Term Art
Weiwei Sun
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
10:29 AM10:29 AM
103 - AZD5582 and Venetoclax Reduce SIV Reservoirs in ART-Suppressed Macaques
Benedicth Ukhueduan
Emory University, Atlanta, GA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
104 - HIV GAG x CD3 Soluble TCR Bispecific Reduces the Active HIV Reservoir in a Phase I/II Trial
Beatriz Mothe
Fundació Lluita contra la SIDA, Badalona, Spain
11:08 AM11:08 AM
105 - Evaluation of 2 bNAbs Plus Vesatolimod in Early-Treated South African Women With HIV-1 During ATI
Thumbi Ndung'u
Africa Health Research Institute, Mtubatuba, South Africa
11:16 AM11:16 AM
106 - A Single Infusion of CCR5-/- CD4 Tscm Cells Promotes Control of SIV Upon ATI
Ashish A. Sharma
Emory University, Atlanta, GA, USA
11:24 AM11:24 AM
107 - RIO: A Randomised Placebo-Controlled Study of 2 LS-bNAbs in People Treated in Early HIV
Sarah Fidler
Imperial College London, London, UK
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
The Coinfections: Hepatitis and TB
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
108 - Trends in Hepatitis C Virus (HCV) Infection Incidence Among PWH Engaged in Care in the US: 1995-2023
Yotam Arens
Weill Cornell Medicine, New York, NY, USA
10:13 AM10:13 AM
109 - HIV Decreases Both Hepatitis B Antibody Titer and Neutralization After Spontaneous HBV Control
Chloe Thio
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
110 - HBV Care Continuum and Associated Factors in Rwanda: A Population-Based Study From 2016-2023
Jean Damascene Makuza
University of British Columbia, Vancouver, Canada
10:29 AM10:29 AM
111 - Intrahepatic Transcriptomics in HBV-HIV Co-Infection Uncover Host Responses to HBV Transcription
Che-Min Lo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
112 - Highly Durable Seroprotection With HepB-CpG Vaccine in People With HIV (PWH): ACTG A5379 (BEeHIVe)
Kristen Marks
Weill Cornell Medicine, New York, NY, USA
11:08 AM11:08 AM
113 - Epigenetic Age Predictors of Semaglutide-Related Liver Fat Changes in People With HIV
Alina Pang
Weill Cornell Medicine, New York, NY, USA
11:16 AM11:16 AM
114 - Supplemental High-Dose Rifampicin and Levofloxacin for Inpatients With Disseminated HIV-TB
Graeme Meintjes
University of Cape Town, Cape Town, South Africa
11:24 AM11:24 AM
115 - Casual Contact in Community Settings Explains Majority of TB Transmission in South Africa
Neel R. Gandhi
Emory University, Atlanta, GA, USA
11:32 AM11:32 AM
116 - DOLPHIN-Moms: Pharmacokinetics of Dolutegravir and HIV Viral Suppression With 1HP or 3HP in Pregnancy
Jyoti Mathad
Weill Cornell Medicine, New York, NY, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Maternal-Child Health and Treatment of Malignancies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
117 - Maternal Tenofovir Prophylaxis With Active Immunization to Prevent Infant Hepatitis B
Gonzague Jourdain
Chiang Mai University, Chiang Mai, Thailand
10:13 AM10:13 AM
118 - Efficacy of Home Visits for Pregnant Couples to Promote Couple HIV Testing and Family Health
Lynae Darbes
University of Michigan, Ann Arbor, MI, USA
10:21 AM10:21 AM
119 - Dolutegravir Does Not Reduce Levonorgestrel or Medroxyprogesterone Acetate Concentrations in WLWH
Rebecca Ryan
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
10:29 AM10:29 AM
120 - Lenacapavir Pharmacokinetics, Safety, and Efficacy in Adolescents and Adults in PURPOSE 1
Katherine Gill
Desmond Tutu HIV Foundation, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
121 - Assessing IIT and Mortality Among CLHIV <15 yo in PEPFAR-Supported Countries, FY21 - FY24
Michelle Yang
US Department of State, Washington, DC, USA
11:08 AM11:08 AM
122 - Multidose PK/Safety of Dolutegravir Dispersible Tablets & Oral Films in Neonates: PETITE-DTG Study
Adrie Bekker
Stellenbosch University, Cape Town, South Africa
11:16 AM11:16 AM
123 - Genotypic Resistance in the African Paediatric CHAPAS-4 Trial of Second-Line Antiretroviral Therapy
Alasdair Bamford
Great Ormond Street NHS Foundation Trust, London, UK
11:24 AM11:24 AM
124 - Abemaciclib, a CDK4/6 Inhibitor, in HIV-Associated and HIV-Negative Kaposi Sarcoma
Jose R. Mercado-Matos
National Cancer Institute, Bethesda, MD, USA
11:32 AM11:32 AM
125 - Differences in Treatment and Overall Survival in People With and Without HIV and Oropharynx Cancer
Elizabeth Chiao
University of Texas MD Anderson Cancer Center, Houston, TX, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Evolution of HIV and Mpox Epidemics
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
126 - Comparing Empirical HIV Incidence With UNAIDS Estimated Incidence Declines in Sub-Saharan Africa
Oliver Stevens
Imperial College London, London, UK
10:21 AM10:21 AM
128 - All-Cause and Cause-Specific Mortality Trends Among Persons With and Without HIV in Rural Tanzania
Julie Ambia
University of Bristol, Bristol, UK
10:29 AM10:29 AM
129 - Associations of Dolutegravir and the COVID-19 Pandemic on Viral Suppression in South African Adults
Haroon Moolla
University of Cape Town, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
130 - A Multistage Sampling Approach to Refine HIV Mortality Estimates in KwaZulu-Natal, South Africa
Alastair VanHeerden
Human Sciences Research Council, Pretoria, South Africa
11:08 AM11:08 AM
131 - Genotypic Characterization of Mpox and a Tale of 2 Co-Circulating Viruses in Uganda
Nicholas Bbosa
London School of Hygiene & Tropical Medicine, London, UK
11:16 AM11:16 AM
132 - Characterization of Mpox Cases in Uganda: Diversity of the Confirmed Cases
Ritah Namusoosa
Ministry of Health Uganda, Kampala, Uganda
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Down But Not Out: Elite Control of HIV
1:30 PM1:30 PM
(Session Overview)
Javier Martinez-Pìcado
IrsiCaixa, Badalona, Spain
1:35 PM1:35 PM
495 - Effect of ART Start Time, ART Duration, and Elite Control on HIV Transcription
Adam Wedrychowski
San Francisco VA Medical Center, San Francisco, CA, USA
1:40 PM1:40 PM
496 - Viral Reservoir Characteristics in Lymphoid Tissues of HIV-1 Elite Controllers
Samantha K. Marzi
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
1:45 PM1:45 PM
497 - CD8+ T Cells Shape the HIV Integration Site Landscape According to the Degree of T-Cell Pressure
Noemi L. Linden
Weill Cornell Medicine, New York, NY, USA
1:50 PM1:50 PM
498 - Anti-IL-10/Anti-PD-1 Dual Blockade Leads to IFN-Related HIV Elite Control Signatures
Susan P. Ribeiro
Emory University, Atlanta, GA, USA
1:55 PM1:55 PM
494 - Loss of Virological Control 32 Years After HIV-1 Diagnosis in an Exceptional Elite Controller
Anna Pons-Grífols
IrsiCaixa, Badalona, Spain
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Heart Failure: Hiding in Plain Sight
1:30 PM1:30 PM
(Session Overview)
Anoop Shah
London School of Hygiene & Tropical Medicine, London, UK
1:35 PM1:35 PM
813 - Mitochondrial Haplogroups and Left Ventricular Dysfunction in People Living With and Without HIV
Craig Cronin
The Johns Hopkins Hospital, Baltimore, MD, USA
1:40 PM1:40 PM
811 - Sex Differences in Myocardial Steatosis in South African Youth With Perinatally-Acquired HIV
Morne Kahts
University of Cape Town, Cape Town, South Africa
1:45 PM1:45 PM
814 - Physician-Confirmed Incident Heart Failure Phenotypes and Etiologies Within CNICS
Matthew J. Feinstein
Northwestern University, Chicago, IL, USA
1:50 PM1:50 PM
815 - Readmission Risk for Adults With HIV Hospitalized for Heart Failure or Acute Myocardial Infarction
Ping Yang
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:55 PM1:55 PM
812 - Heart Failure Among People With HIV: Prescription of Guideline-Directed Medical Therapy
Melissa K. Cutshaw
Duke University School of Medicine, Durham, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
KS and KSHV: New Developments in Diagnosis, Therapy, and Pathogenesis
1:30 PM1:30 PM
(Session Overview)
Robert Yarchoan
National Institutes of Health, Bethesda, MD, USA
1:35 PM1:35 PM
789 - Validation of Quantification of Lesional KSHV DNA Content for Diagnosis of Kaposi Sarcoma in Africa
Aggrey Semeere
Infectious Diseases Institute, Kampala, Uganda
1:40 PM1:40 PM
792 - Impact of Low-Dose Intra-Lesional Nivolumab for Kaposi Sarcoma on T-Cell Proliferation and Function
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
1:45 PM1:45 PM
791 - Immunologic Responses to Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma Treatment
Matthew Witterholt
National Cancer Institute, Bethesda, MD, USA
1:50 PM1:50 PM
794 - Causes of Death Among Adults With HIV-Associated Kaposi Sarcoma in East Africa in the Treat All Era
Hilda Muwando
Infectious Diseases Institute, Kampala, Uganda
1:55 PM1:55 PM
796 - Genome Evolution of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in PLWH
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Meeting the Treatment and Prevention Needs of Transgender Women
1:30 PM1:30 PM
(Session Overview)
Tonia Poteat
Duke University, Durham, NC, USA
1:35 PM1:35 PM
1108 - Recent HIV Acquisition Among Transgender Women From Midwest Brazil
Sylvia L. M. Teixeira
Oswaldo Cruz Institute – Fiocruz, Rio de Janeiro, Brazil
1:45 PM1:45 PM
1109 - High HIV Burden Among Transgender Women in the State Capital and Rural Towns in Central Brazil
Bruno Vinícius D. Diniz e Silva
Federal University of Goias, Goiânia, Brazil
1:50 PM1:50 PM
1110 - Time to Antiretroviral Initiation Among Transgender Women Living With HIV in France (1997-2022)
Juliette Hemery
French National Institute of Health and Medical Research (Inserm), Paris, France
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
HIV Self-Testing: Here and Now
1:30 PM1:30 PM
(Session Overview)
Mateo Prochazka
World Health Organization, Geneva, Switzerland
1:40 PM1:40 PM
1178 - National HIV Self-Test Distribution Program: HIV Testing, Diagnosis and Treatment, 3/2023 - 5/2024
Patrick S. Sullivan
Emory University, Atlanta, GA, USA
1:45 PM1:45 PM
1179 - Estimating Need for Annual HIV Testing Met by a Nationwide Mailed HIV Self-Testing Program
Jen Hecht
1:50 PM1:50 PM
1181 - Moderators of a Home-Based Couple Intervention on Couple HIV Testing and Counselling Uptake in Kenya
Zachary A. Kwena
Kenya Medical Research Institute-UCSF Infectious Disease Research Training Program, Kisumu, Kenya
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Deciphering the Mystery of Viral Rebound
4:00 PM4:00 PM
18 - Utilizing a Barcoded Virus Model to Identify the Source of Viral Rebound
Brandon Keele
Frederick National Laboratory for Cancer Research, Frederick, MD, USA
4:20 PM4:20 PM
19 - Cellular and Tissue Sources of Viral Persistence and Rebound
Linos Vandekerckhove
HIV Cure Research Center, Ghent University, Ghent, Belgium
4:40 PM4:40 PM
20 - Immune Responses During Viral Rebound
Rachel Rutishauser
University of California San Francisco, San Francisco, CA, USA
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Filling the Gaps: Challenges and Opportunities in the Care of Children and Youth With Perinatal HIV
4:00 PM4:00 PM
21 - Advanced HIV Disease in Children
Pablo Rojo
Hospital Universitario 12 de Octubre, Madrid, Spain
4:20 PM4:20 PM
22 - HIV Care Continuum in Children
Irene Njuguna
University of Washington, Seattle, WA, USA
4:40 PM4:40 PM
23 - Sexual, Reproductive, and Pregnancy Health Among People With Perinatal HIV
Caroline Foster
Imperial College Healthcare NHS Trust, London, UK
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Closing the Gaps in the HIV Response
4:00 PM4:00 PM
24 - Immediate Challenges and Long-Term Goals of the HIV Response
Jeffrey Imai-Eaton
Harvard TH Chan School of Public Health
4:20 PM4:20 PM
25 - Integration and Sustainability of the Global HIV Response
Tsitsi Apollo
Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe
4:40 PM4:40 PM
26 - Innovations in HIV Service Delivery: Building a Path Forward with Those Left Behind
Izukanji Sikazwe
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestMiddleName 2 TestLastName 2
Institution 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 3 TestMiddleName 3 TestLastName 3
Institution 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 4 TestMiddleName 4 TestLastName 4
Institution 4
MAR10
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 4
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestMiddleName 2 TestLastName 2
Institution 2
Previous:
MAR10
8:30 AMto9:30 AMPDT
12:00 PMto5:00 PMPDT
Monday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Monday
Diane V. Havlir
University of California San Francisco, San Francisco, CA, USA
8:35 AM8:35 AM
16 - HIV Cure: A Translational Research Perspective
Ole Søgaard
Aarhus University, Aarhus, Denmark
9:05 AM9:05 AM
17 - The Global HIV/AIDS Pandemic: Where Are We Now?
Chris Beyrer
Duke Global Health Institute, Durham, NC, USA
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
HIV Reservoirs and Cure Strategies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
100 - 5’Leader Defects in HIV Plasma Clones Drive 80% of Persistent Viremia on Long-Term ART
Francesco R. Simonetti
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:13 AM10:13 AM
101 - BACH2-Driven Tissue Resident Memory Programs Promote HIV-1 Persistence
Yulong Wei
Yale University, New Haven, CT, USA
10:21 AM10:21 AM
102 - Longitudinal Co-Evolution of HIV-1 Reservoir Cells and Immune Effector Cells During Long-Term Art
Weiwei Sun
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
10:29 AM10:29 AM
103 - AZD5582 and Venetoclax Reduce SIV Reservoirs in ART-Suppressed Macaques
Benedicth Ukhueduan
Emory University, Atlanta, GA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
104 - HIV GAG x CD3 Soluble TCR Bispecific Reduces the Active HIV Reservoir in a Phase I/II Trial
Beatriz Mothe
Fundació Lluita contra la SIDA, Badalona, Spain
11:08 AM11:08 AM
105 - Evaluation of 2 bNAbs Plus Vesatolimod in Early-Treated South African Women With HIV-1 During ATI
Thumbi Ndung'u
Africa Health Research Institute, Mtubatuba, South Africa
11:16 AM11:16 AM
106 - A Single Infusion of CCR5-/- CD4 Tscm Cells Promotes Control of SIV Upon ATI
Ashish A. Sharma
Emory University, Atlanta, GA, USA
11:24 AM11:24 AM
107 - RIO: A Randomised Placebo-Controlled Study of 2 LS-bNAbs in People Treated in Early HIV
Sarah Fidler
Imperial College London, London, UK
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
The Coinfections: Hepatitis and TB
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
108 - Trends in Hepatitis C Virus (HCV) Infection Incidence Among PWH Engaged in Care in the US: 1995-2023
Yotam Arens
Weill Cornell Medicine, New York, NY, USA
10:13 AM10:13 AM
109 - HIV Decreases Both Hepatitis B Antibody Titer and Neutralization After Spontaneous HBV Control
Chloe Thio
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
110 - HBV Care Continuum and Associated Factors in Rwanda: A Population-Based Study From 2016-2023
Jean Damascene Makuza
University of British Columbia, Vancouver, Canada
10:29 AM10:29 AM
111 - Intrahepatic Transcriptomics in HBV-HIV Co-Infection Uncover Host Responses to HBV Transcription
Che-Min Lo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
112 - Highly Durable Seroprotection With HepB-CpG Vaccine in People With HIV (PWH): ACTG A5379 (BEeHIVe)
Kristen Marks
Weill Cornell Medicine, New York, NY, USA
11:08 AM11:08 AM
113 - Epigenetic Age Predictors of Semaglutide-Related Liver Fat Changes in People With HIV
Alina Pang
Weill Cornell Medicine, New York, NY, USA
11:16 AM11:16 AM
114 - Supplemental High-Dose Rifampicin and Levofloxacin for Inpatients With Disseminated HIV-TB
Graeme Meintjes
University of Cape Town, Cape Town, South Africa
11:24 AM11:24 AM
115 - Casual Contact in Community Settings Explains Majority of TB Transmission in South Africa
Neel R. Gandhi
Emory University, Atlanta, GA, USA
11:32 AM11:32 AM
116 - DOLPHIN-Moms: Pharmacokinetics of Dolutegravir and HIV Viral Suppression With 1HP or 3HP in Pregnancy
Jyoti Mathad
Weill Cornell Medicine, New York, NY, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Maternal-Child Health and Treatment of Malignancies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
117 - Maternal Tenofovir Prophylaxis With Active Immunization to Prevent Infant Hepatitis B
Gonzague Jourdain
Chiang Mai University, Chiang Mai, Thailand
10:13 AM10:13 AM
118 - Efficacy of Home Visits for Pregnant Couples to Promote Couple HIV Testing and Family Health
Lynae Darbes
University of Michigan, Ann Arbor, MI, USA
10:21 AM10:21 AM
119 - Dolutegravir Does Not Reduce Levonorgestrel or Medroxyprogesterone Acetate Concentrations in WLWH
Rebecca Ryan
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
10:29 AM10:29 AM
120 - Lenacapavir Pharmacokinetics, Safety, and Efficacy in Adolescents and Adults in PURPOSE 1
Katherine Gill
Desmond Tutu HIV Foundation, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
121 - Assessing IIT and Mortality Among CLHIV <15 yo in PEPFAR-Supported Countries, FY21 - FY24
Michelle Yang
US Department of State, Washington, DC, USA
11:08 AM11:08 AM
122 - Multidose PK/Safety of Dolutegravir Dispersible Tablets & Oral Films in Neonates: PETITE-DTG Study
Adrie Bekker
Stellenbosch University, Cape Town, South Africa
11:16 AM11:16 AM
123 - Genotypic Resistance in the African Paediatric CHAPAS-4 Trial of Second-Line Antiretroviral Therapy
Alasdair Bamford
Great Ormond Street NHS Foundation Trust, London, UK
11:24 AM11:24 AM
124 - Abemaciclib, a CDK4/6 Inhibitor, in HIV-Associated and HIV-Negative Kaposi Sarcoma
Jose R. Mercado-Matos
National Cancer Institute, Bethesda, MD, USA
11:32 AM11:32 AM
125 - Differences in Treatment and Overall Survival in People With and Without HIV and Oropharynx Cancer
Elizabeth Chiao
University of Texas MD Anderson Cancer Center, Houston, TX, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Evolution of HIV and Mpox Epidemics
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
126 - Comparing Empirical HIV Incidence With UNAIDS Estimated Incidence Declines in Sub-Saharan Africa
Oliver Stevens
Imperial College London, London, UK
10:21 AM10:21 AM
128 - All-Cause and Cause-Specific Mortality Trends Among Persons With and Without HIV in Rural Tanzania
Julie Ambia
University of Bristol, Bristol, UK
10:29 AM10:29 AM
129 - Associations of Dolutegravir and the COVID-19 Pandemic on Viral Suppression in South African Adults
Haroon Moolla
University of Cape Town, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
130 - A Multistage Sampling Approach to Refine HIV Mortality Estimates in KwaZulu-Natal, South Africa
Alastair VanHeerden
Human Sciences Research Council, Pretoria, South Africa
11:08 AM11:08 AM
131 - Genotypic Characterization of Mpox and a Tale of 2 Co-Circulating Viruses in Uganda
Nicholas Bbosa
London School of Hygiene & Tropical Medicine, London, UK
11:16 AM11:16 AM
132 - Characterization of Mpox Cases in Uganda: Diversity of the Confirmed Cases
Ritah Namusoosa
Ministry of Health Uganda, Kampala, Uganda
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Down But Not Out: Elite Control of HIV
1:30 PM1:30 PM
(Session Overview)
Javier Martinez-Pìcado
IrsiCaixa, Badalona, Spain
1:35 PM1:35 PM
495 - Effect of ART Start Time, ART Duration, and Elite Control on HIV Transcription
Adam Wedrychowski
San Francisco VA Medical Center, San Francisco, CA, USA
1:40 PM1:40 PM
496 - Viral Reservoir Characteristics in Lymphoid Tissues of HIV-1 Elite Controllers
Samantha K. Marzi
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
1:45 PM1:45 PM
497 - CD8+ T Cells Shape the HIV Integration Site Landscape According to the Degree of T-Cell Pressure
Noemi L. Linden
Weill Cornell Medicine, New York, NY, USA
1:50 PM1:50 PM
498 - Anti-IL-10/Anti-PD-1 Dual Blockade Leads to IFN-Related HIV Elite Control Signatures
Susan P. Ribeiro
Emory University, Atlanta, GA, USA
1:55 PM1:55 PM
494 - Loss of Virological Control 32 Years After HIV-1 Diagnosis in an Exceptional Elite Controller
Anna Pons-Grífols
IrsiCaixa, Badalona, Spain
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Heart Failure: Hiding in Plain Sight
1:30 PM1:30 PM
(Session Overview)
Anoop Shah
London School of Hygiene & Tropical Medicine, London, UK
1:35 PM1:35 PM
813 - Mitochondrial Haplogroups and Left Ventricular Dysfunction in People Living With and Without HIV
Craig Cronin
The Johns Hopkins Hospital, Baltimore, MD, USA
1:40 PM1:40 PM
811 - Sex Differences in Myocardial Steatosis in South African Youth With Perinatally-Acquired HIV
Morne Kahts
University of Cape Town, Cape Town, South Africa
1:45 PM1:45 PM
814 - Physician-Confirmed Incident Heart Failure Phenotypes and Etiologies Within CNICS
Matthew J. Feinstein
Northwestern University, Chicago, IL, USA
1:50 PM1:50 PM
815 - Readmission Risk for Adults With HIV Hospitalized for Heart Failure or Acute Myocardial Infarction
Ping Yang
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:55 PM1:55 PM
812 - Heart Failure Among People With HIV: Prescription of Guideline-Directed Medical Therapy
Melissa K. Cutshaw
Duke University School of Medicine, Durham, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
KS and KSHV: New Developments in Diagnosis, Therapy, and Pathogenesis
1:30 PM1:30 PM
(Session Overview)
Robert Yarchoan
National Institutes of Health, Bethesda, MD, USA
1:35 PM1:35 PM
789 - Validation of Quantification of Lesional KSHV DNA Content for Diagnosis of Kaposi Sarcoma in Africa
Aggrey Semeere
Infectious Diseases Institute, Kampala, Uganda
1:40 PM1:40 PM
792 - Impact of Low-Dose Intra-Lesional Nivolumab for Kaposi Sarcoma on T-Cell Proliferation and Function
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
1:45 PM1:45 PM
791 - Immunologic Responses to Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma Treatment
Matthew Witterholt
National Cancer Institute, Bethesda, MD, USA
1:50 PM1:50 PM
794 - Causes of Death Among Adults With HIV-Associated Kaposi Sarcoma in East Africa in the Treat All Era
Hilda Muwando
Infectious Diseases Institute, Kampala, Uganda
1:55 PM1:55 PM
796 - Genome Evolution of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in PLWH
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Meeting the Treatment and Prevention Needs of Transgender Women
1:30 PM1:30 PM
(Session Overview)
Tonia Poteat
Duke University, Durham, NC, USA
1:35 PM1:35 PM
1108 - Recent HIV Acquisition Among Transgender Women From Midwest Brazil
Sylvia L. M. Teixeira
Oswaldo Cruz Institute – Fiocruz, Rio de Janeiro, Brazil
1:45 PM1:45 PM
1109 - High HIV Burden Among Transgender Women in the State Capital and Rural Towns in Central Brazil
Bruno Vinícius D. Diniz e Silva
Federal University of Goias, Goiânia, Brazil
1:50 PM1:50 PM
1110 - Time to Antiretroviral Initiation Among Transgender Women Living With HIV in France (1997-2022)
Juliette Hemery
French National Institute of Health and Medical Research (Inserm), Paris, France
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
HIV Self-Testing: Here and Now
1:30 PM1:30 PM
(Session Overview)
Mateo Prochazka
World Health Organization, Geneva, Switzerland
1:40 PM1:40 PM
1178 - National HIV Self-Test Distribution Program: HIV Testing, Diagnosis and Treatment, 3/2023 - 5/2024
Patrick S. Sullivan
Emory University, Atlanta, GA, USA
1:45 PM1:45 PM
1179 - Estimating Need for Annual HIV Testing Met by a Nationwide Mailed HIV Self-Testing Program
Jen Hecht
1:50 PM1:50 PM
1181 - Moderators of a Home-Based Couple Intervention on Couple HIV Testing and Counselling Uptake in Kenya
Zachary A. Kwena
Kenya Medical Research Institute-UCSF Infectious Disease Research Training Program, Kisumu, Kenya
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Deciphering the Mystery of Viral Rebound
4:00 PM4:00 PM
18 - Utilizing a Barcoded Virus Model to Identify the Source of Viral Rebound
Brandon Keele
Frederick National Laboratory for Cancer Research, Frederick, MD, USA
4:20 PM4:20 PM
19 - Cellular and Tissue Sources of Viral Persistence and Rebound
Linos Vandekerckhove
HIV Cure Research Center, Ghent University, Ghent, Belgium
4:40 PM4:40 PM
20 - Immune Responses During Viral Rebound
Rachel Rutishauser
University of California San Francisco, San Francisco, CA, USA
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Filling the Gaps: Challenges and Opportunities in the Care of Children and Youth With Perinatal HIV
4:00 PM4:00 PM
21 - Advanced HIV Disease in Children
Pablo Rojo
Hospital Universitario 12 de Octubre, Madrid, Spain
4:20 PM4:20 PM
22 - HIV Care Continuum in Children
Irene Njuguna
University of Washington, Seattle, WA, USA
4:40 PM4:40 PM
23 - Sexual, Reproductive, and Pregnancy Health Among People With Perinatal HIV
Caroline Foster
Imperial College Healthcare NHS Trust, London, UK
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Closing the Gaps in the HIV Response
4:00 PM4:00 PM
24 - Immediate Challenges and Long-Term Goals of the HIV Response
Jeffrey Imai-Eaton
Harvard TH Chan School of Public Health
4:20 PM4:20 PM
25 - Integration and Sustainability of the Global HIV Response
Tsitsi Apollo
Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe
4:40 PM4:40 PM
26 - Innovations in HIV Service Delivery: Building a Path Forward with Those Left Behind
Izukanji Sikazwe
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestMiddleName 2 TestLastName 2
Institution 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 3 TestMiddleName 3 TestLastName 3
Institution 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 4 TestMiddleName 4 TestLastName 4
Institution 4
MAR10
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 4
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestMiddleName 2 TestLastName 2
Institution 2
